S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Forecast, Price & News

$10.00
-0.08 (-0.79%)
(As of 06/2/2023 ET)
Compare
Today's Range
$9.99
$10.26
50-Day Range
$6.61
$10.57
52-Week Range
$4.12
$17.06
Volume
143,163 shs
Average Volume
294,665 shs
Market Capitalization
$341.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33

KalVista Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.3% Upside
$19.33 Price Target
Short Interest
Bearish
15.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
1.00mentions of KalVista Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$124,398 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.61) to ($3.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

534th out of 983 stocks

Pharmaceutical Preparations Industry

262nd out of 486 stocks


KALV stock logo

About KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALV Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
See More Headlines

KALV Price History

KALV Company Calendar

Last Earnings
3/09/2023
Today
6/02/2023
Next Earnings (Estimated)
7/06/2023
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KALV
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.33
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+93.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-82,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.54 per share

Miscellaneous

Free Float
31,333,000
Market Cap
$341.70 million
Optionable
Not Optionable
Beta
1.11

Key Executives

  • Mr. Thomas Andrew Crockett M.B.A.Mr. Thomas Andrew Crockett M.B.A. (Age 48)
    CEO & Director
    Comp: $980.25k
  • Mr. Benjamin L. Palleiko (Age 57)
    Chief Bus. Officer & CFO
    Comp: $722.83k
  • Dr. Christopher M. Yea Ph.D. (Age 59)
    Chief Devel. Officer
    Comp: $664.28k
  • Dr. Edward P. Feener Ph.D. (Age 63)
    Chief Scientific Officer
  • Jarrod Aldom
    VP of Corp. Communications
  • Ms. Rachel M. Morten
    Sr. VP of Regulatory Affairs & QA
  • Dr. Michael D. Smith Pharm.D. (Age 44)
    Sr. VP of Devel.
  • Dr. Paul K. Audhya M.B.A. (Age 51)
    M.D., Chief Medical Officer
  • Mr. Stephen Donnelly
    Director of Fin. and Company Sec.
  • Mr. John B. McKune (Age 47)
    VP of Fin.













KALV Stock - Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares.
View KALV analyst ratings
or view top-rated stocks.

What is KalVista Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1-year price targets for KalVista Pharmaceuticals' stock. Their KALV share price forecasts range from $16.00 to $22.00. On average, they expect the company's stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price.
View analysts price targets for KALV
or view top-rated stocks among Wall Street analysts.

How have KALV shares performed in 2023?

KalVista Pharmaceuticals' stock was trading at $6.76 at the beginning of the year. Since then, KALV stock has increased by 47.9% and is now trading at $10.00.
View the best growth stocks for 2023 here
.

When is KalVista Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023.
View our KALV earnings forecast
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Thursday, March, 9th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.22.

What ETFs hold KalVista Pharmaceuticals' stock?

ETFs with the largest weight of KalVista Pharmaceuticals (NASDAQ:KALV) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Who are KalVista Pharmaceuticals' major shareholders?

KalVista Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (5.80%), Boxer Capital LLC (4.83%), Great Point Partners LLC (4.68%), BlackRock Inc. (4.56%), Saturn V Capital Management LLC (3.28%) and Geode Capital Management LLC (1.37%). Insiders that own company stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya and Thomas Andrew Crockett.
View institutional ownership trends
.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $10.00.

How much money does KalVista Pharmaceuticals make?

KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $341.70 million. The specialty pharmaceutical company earns $-82,340,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for the company is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at ir@kalvista.com, or via fax at 866-553-3269.

This page (NASDAQ:KALV) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -